scholarly journals The potential role of vitamin C in empowering cancer immunotherapy

2022 ◽  
Vol 146 ◽  
pp. 112553
Author(s):  
Takwa Bedhiafi ◽  
Varghese Philipose Inchakalody ◽  
Queenie Fernandes ◽  
Sarra Mestiri ◽  
Nashiru Billa ◽  
...  
2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Teresa Maria Tomasa-Irriguible ◽  
Lara Bielsa-Berrocal

AbstractThere are limited proven therapeutic options for the prevention and treatment of COVID-19. We underwent an observational study with the aim of measure plasma vitamin C levels in a population of critically ill COVID-19 adult patients who met ARDS criteria according to the Berlin definition. This epidemiological study brings to light that up to 82% had low Vitamin C values. Notwithstanding the limitation that this is a single-center study, it nevertheless shows an important issue. Given the potential role of vitamin C in sepsis and ARDS, there is gathering interest of whether supplementation could be beneficial in COVID-19.


2021 ◽  
Vol 8 ◽  
pp. 2333794X2110217
Author(s):  
Indah K. Murni ◽  
Endy P. Prawirohartono ◽  
Rina Triasih

Background. Vitamin C, E, D, A, zinc are considered to be essential in preventing and treating of acute respiratory infections (ARI) including COVID-19. Methods. We reviewed published studies evaluating the potential roles of these vitamin and zinc for ARIs and COVID-19 using Medline database, medRxiv, and bibliographic references. Results. Vitamins C, D, and E did not reduce incidence of common cold in general, but vitamin C reduced by half in population with physical and environment stresses. Vitamins C and E shortened duration and reduced severity of common cold. A large-dose vitamin A had no effect on recovery from pneumonia. Zinc improved clinical deterioration and pneumonia duration in under five. The effect on preventing COVID-19 morbidity and related-death was lacking. Conclusions. Although the effects of vitamins and zinc on ARIs including COVID-19 were inconclusive, taking these for a short period during pandemic may be beneficial when there is risks of deficiency.


2020 ◽  
Vol 27 (9) ◽  
pp. 9843-9852 ◽  
Author(s):  
Mahmoud A. O. Dawood ◽  
Mohsen Zommara ◽  
Nabil M. Eweedah ◽  
Azmy I. Helal ◽  
Mohamed A. Aboel-Darag

2021 ◽  
Vol 12 ◽  
Author(s):  
Yan Yang ◽  
Zheng Yang ◽  
Yun Yang

The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immunotherapy, are currently in clinical research. In our review of CD47-targeted bsAbs, we described the fundamental of bsAbs. Then, we summarized the information of four undergoing phase I researches, reviewed the main toxicities relevant to CD47-targeted bsAb immunological therapy of on-target cytotoxicity to healthy cells and a remarkable antigen-sink. Finally, we described possible mechanisms of resistance to CD47-targeted bsAb therapy. More clinical researches are supposed to adequately confirm its security and efficacy in clinical practice.


Sign in / Sign up

Export Citation Format

Share Document